» Articles » PMID: 10028918

Temporal Expression Pattern of Peripheral Myelin Protein 22 During in Vivo and in Vitro Myelination

Overview
Journal Glia
Specialty Neurology
Date 1999 Feb 24
PMID 10028918
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

Peripheral myelin protein 22 (PMP22) was initially described as a minor component of peripheral myelin. Mutations affecting the PMP22 gene cause demyelinating neuropathies, supporting a role for the protein in PNS myelination. Furthermore, PMP22 carries the L2/HNK-1 carbohydrate epitope suggesting an adhesion/recognition function. Despite advances in characterizing the PMP22 gene, the specific role(s) of the protein in myelin remains unknown. In this study we determined the temporal expression pattern of PMP22 in comparison to galactocerebroside (GalC) and myelin associated glycoprotein (MAG), early constituents of PNS myelin, and to protein zero (P0) and myelin basic protein (MBP), late components of myelin. In sciatic nerve lysates, PMP22 was detected at postnatal day 3, after MAG, but before MBP expression. The same results were obtained in cocultures of dorsal root ganglion neurons and Schwann cells (SCs). Low levels of PMP22 were found in early, anti-MAG and anti-GalC immunoreactive, myelinating cocultures. However, PMP22 could only be detected in the SC plasma membrane after basal lamina formation. In long-term myelinating cocultures PMP22 levels continued to increase and the protein was found in anti-P0 and anti-MBP immunoreactive myelin segments. Furthermore, PMP22, MBP, and P0 protein levels were greatly enhanced by progesterone treatment of the cocultures. The highest levels of PMP22 expression were associated with late stages of myelination; however the presence of the protein in nonmyelinating SCs and in SCs commencing myelination supports multiple roles for PMP22 in peripheral nerve biology.

Citing Articles

Bone marrow mesenchymal stem cells in treatment of peripheral nerve injury.

Zou X, Zhang B, Qian W, Cheng F World J Stem Cells. 2024; 16(8):799-810.

PMID: 39219723 PMC: 11362854. DOI: 10.4252/wjsc.v16.i8.799.


Quantitative proteomics unveils known and previously unrecognized alterations in neuropathic nerves.

Defilippi V, Petereit J, Handlos V, Notterpek L J Neurochem. 2024; 168(9):3154-3170.

PMID: 39072727 PMC: 11702352. DOI: 10.1111/jnc.16189.


Unraveling the structures, functions and mechanisms of epithelial membrane protein family in human cancers.

Zhang N, Zhu H, Huang W, Wen X, Xie X, Jiang X Exp Hematol Oncol. 2022; 11(1):69.

PMID: 36217151 PMC: 9552464. DOI: 10.1186/s40164-022-00321-x.


Mechanisms and Treatments in Demyelinating CMT.

Fridman V, Saporta M Neurotherapeutics. 2021; 18(4):2236-2268.

PMID: 34750751 PMC: 8804145. DOI: 10.1007/s13311-021-01145-z.


Genome-Edited Coincidence and PMP22-HiBiT Fusion Reporter Cell Lines Enable an Artifact-Suppressive Quantitative High-Throughput Screening Strategy for Gene-Dosage Disorder Drug Discovery.

Martinez N, Braisted J, Dranchak P, Moran J, Larson H, Queme B ACS Pharmacol Transl Sci. 2021; 4(4):1422-1436.

PMID: 34423274 PMC: 8369676. DOI: 10.1021/acsptsci.1c00110.